IGFBPL1: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of IGFBPL1. The page also collects GeneMedi's different modalities and formats products for IGFBPL1 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the IGFBPL1 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Secreted Protein/Potential Cytokines.
Predicted to enable insulin-like growth factor binding activity. Involved in cellular response to tumor cell. Located in extracellular space. [provided by Alliance of Genome Resources, Apr 2022]
Target ID | GM-SE0988 |
Target Name | IGFBPL1 |
Gene ID | 347252,75426,366366,100425543,481621,101091055,616886,100630374 |
Gene Symbol and Synonyms | 2810011G06Rik,2810453O06Rik,bA113O24.1,IGFBP-RP4,IGFBPL,IGFBPL1,IGFBPRP4 |
Uniprot Accession | Q8WX77,A5PKD8 |
Uniprot Entry Name | IBPL1_HUMAN,IBPL1_BOVIN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | Cytokine Target |
Disease | Pregnant state |
Gene Ensembl | ENSG00000137142 |
Target Classification | N/A |
Pre-made anti-IGFBPL1 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-IGFBPL1 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-IGFBPL1 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-IGFBPL1 monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody, Cytokine antibody | Detail |
Recombinant multi-species IBPL1/ IGFBPL1/ IGFBP-RP4 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine IGFBPL1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
IGFBPL1 protein | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Detail |
Cytokine Products for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces human, Cynomolgus/ Rhesus macaque, rat, mouse insulin-like growth factor binding protein-like 1 (IGFBPL1) His+Avi (Biotinylated) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
IGFBPL1 (Insulin Like Growth Factor Binding Protein Like 1) is a Protein Coding gene. Diseases associated with IGFBPL1 include Glaucomatocyclitic Crisis and Vitreous Detachment. Gene Ontology (GO) annotations related to this gene include insulin-like growth factor binding. An important paralog of this gene is IGFBP7.
Target | Species | Antigen Product Name | Bioactivity validation of Antigen | Antibody Product Name | Bioactivity validation of Antibodies | Detail |
IGFBPL1 | Human, Cynomolgus/Rhesus macaque, rat, mouse | insulin-like growth factor binding protein-like 1 (IGFBPL1) protein | Affintiy&bioactivity validated by ELISA, cell culture validated | Anti-IGFBPL1 monoclonal antibody | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). | Detail |
Click to check more Cytokine Products